Parolin M, Baraldi M, Valentini E, Murer L, Vidal E. Comamonas testosteroni-associated peritonitis in a pediatric peritoneal dialysis patient. World J Nephrol 2016; 5(2): 220-223 [PMID: 26981448 DOI: 10.5527/wjn.v5.i2.220]
Corresponding Author of This Article
Enrico Vidal, MD, PhD, Nephrology, Dialysis and Transplant Unit, Department of Women’s and Children’s Health, University-Hospital of Padova, Via Giustiniani, 3, 35128 Padova, Italy. enrico.vidal@inwind.it
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Nephrol. Mar 6, 2016; 5(2): 220-223 Published online Mar 6, 2016. doi: 10.5527/wjn.v5.i2.220
Comamonas testosteroni-associated peritonitis in a pediatric peritoneal dialysis patient
Mattia Parolin, Maura Baraldi, Elena Valentini, Luisa Murer, Enrico Vidal
Mattia Parolin, Maura Baraldi, Elena Valentini, Luisa Murer, Enrico Vidal, Nephrology, Dialysis and Transplant Unit, Department of Women’s and Children’s Health, University-Hospital of Padova, 35128 Padova, Italy
Author contributions: Parolin M, Murer L and Vidal E designed the report; Baraldi M and Valentini E collected the patient’s clinical data; Parolin M, Baraldi M and Vidal E analyzed the data and wrote the paper.
Institutional review board statement: This study reports anonymous clinical data without affecting the patient’s rights and welfare. No IRB approval was required.
Informed consent statement: Written informed consent for clinical case description was obtained from the patient’s parents.
Conflict-of-interest statement: Nothing to disclose.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Enrico Vidal, MD, PhD, Nephrology, Dialysis and Transplant Unit, Department of Women’s and Children’s Health, University-Hospital of Padova, Via Giustiniani, 3, 35128 Padova, Italy. enrico.vidal@inwind.it
Telephone: +39-049-8213596 Fax: +39-049-8211401
Received: August 28, 2015 Peer-review started: September 4, 2015 First decision: November 27, 2015 Revised: December 10, 2015 Accepted: January 21, 2016 Article in press: January 22, 2016 Published online: March 6, 2016 Processing time: 185 Days and 18.7 Hours
Abstract
Comamonas testosteroni (C. testosteroni) has been rarely observed as an infectious agent in clinical practice. Few reports described its potential pathogenicity in bloodstream and abdominal infections. Here, we report our experience in the treatment of a C. testosteroni-associated peritonitis in a four-year-old girl receiving chronic peritoneal dialysis (PD). The organism was shown to be highly susceptible to appropriate antibiotic therapy. Infection responded promptly and the patient was managed conservatively without withdrawal from PD.
Core tip:Comamonas testosteroni (C. testosteroni) has been largely overlooked as a potential pathogen in humans. This case reports not only the first description of a C. testosteroni-associated peritonitis in a pediatric patient, but also emphasizes the risk of uncommon causes of bacterial peritonitis especially in peritoneal dialysis children with severe comorbidities.
